Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

BACKGROUND: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:medRxiv
Glavni autori: Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., van Helmond, Noud, Klassen, Stephen A., Wiggins, Chad C., Bruno, Katelyn A., Golafshar, Michael A., Petersen, Molly M., Buras, Matthew R., Klompas, Allan M., Sexton, Matthew A., Soto, Juan C. Diaz, Baker, Sarah E., Shepherd, John R.A., Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Wright, Katherine, Greenshields, Joel T., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo, Carter, Rickey E., Joyner, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: Cold Spring Harbor Laboratory 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043472/
https://ncbi.nlm.nih.gov/pubmed/33851175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.08.21255115
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items